News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
754,858 Results
Type
Article (45983)
Company Profile (333)
Press Release (708518)
Multimedia
Podcasts (152)
Webinars (25)
Section
Business (213087)
Career Advice (2207)
Deals (37280)
Drug Delivery (144)
Drug Development (84748)
Employer Resources (178)
FDA (17051)
Job Trends (15702)
News (361712)
Policy (34685)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2665)
Accelerated approval (43)
Adcomms (34)
Allergies (169)
Alliances (52245)
ALS (201)
Alzheimer's disease (1786)
Antibody-drug conjugate (ADC) (397)
Approvals (17342)
Artificial intelligence (634)
Autoimmune disease (233)
Automation (50)
Bankruptcy (379)
Best Places to Work (11844)
BIOSECURE Act (22)
Biosimilars (214)
Biotechnology (194)
Bladder cancer (178)
Brain cancer (67)
Breast cancer (702)
Cancer (5461)
Cardiovascular disease (479)
Career advice (1866)
Career pathing (44)
CAR-T (311)
CDC (61)
Celiac Disease (2)
Cell therapy (834)
Cervical cancer (41)
Clinical research (72831)
Collaboration (1997)
Company closure (5)
Compensation (1300)
Complete response letters (83)
COVID-19 (2836)
CRISPR (106)
C-suite (1015)
Cystic fibrosis (154)
Data (7127)
Decentralized trials (3)
Denatured (43)
Depression (160)
Dermatology (58)
Diabetes (571)
Diagnostics (6945)
Digital health (52)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (309)
Drug pricing (229)
Drug shortages (35)
Duchenne muscular dystrophy (273)
Earnings (93272)
Editorial (66)
Employer branding (21)
Employer resources (158)
Events (122615)
Executive appointments (1069)
FDA (20525)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1650)
Gene editing (224)
Generative AI (58)
Gene therapy (691)
GLP-1 (1136)
Government (4928)
Grass and pollen (7)
Guidances (398)
Healthcare (19268)
HIV (75)
Huntington's disease (53)
IgA nephropathy (95)
Immunology and inflammation (306)
Immuno-oncology (87)
Indications (158)
Infectious disease (3163)
Inflammatory bowel disease (211)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (278)
Interviews (345)
IPO (17097)
IRA (58)
Job creations (4179)
Job search strategy (1564)
JPM (71)
Kidney cancer (19)
Labor market (93)
Layoffs (610)
Leadership (42)
Legal (8583)
Liver cancer (100)
Longevity (29)
Lung cancer (733)
Lymphoma (412)
Machine learning (53)
Management (62)
Manufacturing (965)
MASH (188)
Medical device (13988)
Medtech (14065)
Mergers & acquisitions (21349)
Metabolic disorders (1530)
mRNA (189)
Multiple sclerosis (179)
NASH (21)
Neurodegenerative disease (403)
Neuropsychiatric disorders (108)
Neuroscience (3234)
Neurotech (1)
NextGen: Class of 2026 (6743)
Non-profit (4604)
Now hiring (73)
Obesity (748)
Opinion (323)
Ovarian cancer (187)
Pain (247)
Pancreatic cancer (256)
Parkinson's disease (348)
Partnered (34)
Patents (566)
Patient recruitment (602)
Peanut (64)
People (61825)
Pharmaceutical (95)
Pharmacy benefit managers (36)
Phase 1 (22715)
Phase 2 (31985)
Phase 3 (23943)
Pipeline (7203)
Policy (335)
Postmarket research (2687)
Preclinical (9574)
Press Release (68)
Prostate cancer (280)
Psychedelics (52)
Radiopharmaceuticals (313)
Rare diseases (1051)
Real estate (6421)
Recruiting (72)
Regulatory (26255)
Reports (54)
Research institute (2483)
Resumes & cover letters (374)
Rett syndrome (32)
RNA editing (19)
RSV (93)
Schizophrenia (173)
Series A (275)
Series B (206)
Service/supplier (14)
Sickle cell disease (110)
Special edition (28)
Spinal muscular atrophy (171)
Sponsored (46)
Startups (3846)
State (2)
Stomach cancer (20)
Supply chain (124)
Tariffs (101)
The Weekly (106)
Vaccines (1118)
Venture capital (105)
Weight loss (507)
Women's health (111)
Worklife (20)
Date
Last 7 days (651)
Last 30 days (2493)
Last 365 days (30751)
2026 (8219)
2025 (31087)
2024 (36145)
2023 (40942)
2022 (52137)
2021 (56690)
2020 (55114)
2019 (47837)
2018 (36149)
2017 (33581)
2016 (33176)
2015 (39017)
2014 (32966)
2013 (28080)
2012 (30171)
2011 (30874)
2010 (28895)
Location
Africa (831)
Alabama (91)
Alaska (7)
Arizona (340)
Arkansas (15)
Asia (43413)
Australia (6897)
California (12371)
Canada (3546)
China (1291)
Colorado (528)
Connecticut (525)
Delaware (373)
Europe (93707)
Florida (1884)
Georgia (394)
Hawaii (3)
Idaho (62)
Illinois (978)
India (83)
Indiana (574)
Iowa (22)
Japan (502)
Kansas (130)
Kentucky (44)
Louisiana (40)
Maine (73)
Maryland (1504)
Massachusetts (8885)
Michigan (350)
Minnesota (681)
Mississippi (6)
Missouri (138)
Montana (33)
Nebraska (29)
Nevada (139)
New Hampshire (82)
New Jersey (3318)
New Mexico (31)
New York (3268)
North Carolina (1624)
North Dakota (8)
Northern California (6101)
Ohio (371)
Oklahoma (23)
Oregon (47)
Pennsylvania (2509)
Puerto Rico (27)
Rhode Island (50)
South America (1200)
South Carolina (77)
South Dakota (1)
Southern California (4857)
Tennessee (202)
Texas (1953)
United States (44045)
Utah (372)
Vermont (1)
Virginia (309)
Washington D.C. (81)
Washington State (993)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
754,858 Results for "delta pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax
March 3, 2025
·
1 min read
Approvals
Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights
Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million payment.
March 18, 2026
·
3 min read
·
Annalee Armstrong
Drug Development
Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323
Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323.
February 2, 2024
·
1 min read
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
·
7 min read
·
Dan Samorodnitsky
Press Releases
Arna Pharma Inc. and Slate Run Pharmaceuticals to form a Joint Venture to Create Scaled-Up U.S. Specialty Pharmaceutical Platform
February 26, 2026
·
3 min read
Press Releases
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
December 17, 2025
·
9 min read
Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
In this episode of Denatured, you’ll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, chief medical officer at VectorY Therapeutics. We’ll be speaking about patient-pharma collaborations accelerating trials and hope, advances in ALS biology understanding and biomarker-driven endpoints.
February 26, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Press Releases
Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729
December 5, 2024
·
1 min read
Press Releases
Ferring Pharmaceuticals Presents Two New Analyses of Pivotal Trial Data for Follitropin Delta (FE 999049) at ASRM 2025
October 28, 2025
·
6 min read
Drug Development
Delta-Fly Pharma Inc.: Update on the Interim Analysis Status of Phase III Study of DFP-10917 in the patients with R/R AML
Delta-Fly Pharma Inc.: Update on the Interim Analysis Status of Phase III Study of DFP-10917 in the patients with R/R AML.
January 30, 2024
·
1 min read
Previous
2 of 75,486
Next
